C onveCtion-enhanCed delivery (CED) enables localized drug delivery to tissues using positive pressure to induce convective flow of molecules and achieve greater distribution of drug than other diffusion-based methods. CED is of particular interest in treating tumors of the CNS as it overcomes the blood-brain barrier (BBB), currently a central limitation of drug delivery for these tumors. The efficacy of CED is limited by factors such as infusion rate, with higher rates reaching a larger volume of distribution but increasing the likelihood of adverse complications.
C onveCtion-enhanCed delivery (CED) enables localized drug delivery to tissues using positive pressure to induce convective flow of molecules and achieve greater distribution of drug than other diffusion-based methods. CED is of particular interest in treating tumors of the CNS as it overcomes the blood-brain barrier (BBB), currently a central limitation of drug delivery for these tumors. The efficacy of CED is limited by factors such as infusion rate, with higher rates reaching a larger volume of distribution but increasing the likelihood of adverse complications. 12 Additionally, selection of a target and accuracy of catheter placement factor into CED success, both in regard to drug distribution and mitigating risk of injury to structures that must be traversed. 16, 18, 19 Furthermore, the effect of ependymal and pial surfaces on drug delivery through CED in brainstem tumors remains controversial. Specifically, one study identified a drastic decrease in the ratio of infusion volume to the volume of distribution of the drug when the infusion front reached the pial surface. 10 Others found that leakage into the subarachnoid space might be possible through the ependymal surface, but that the pia provides an absolute bar-ABBREVIATIONS BBB = blood-brain barrier; CED = convection-enhanced delivery; DIPG = diffuse intrinsic pontine glioma. Influence of an intratumoral cyst on drug distribution by convection-enhanced delivery: case report rier for large molecules unless it is perforated by the catheter. 18 Furthermore, it has been suggested that selecting targets away from cystic structures can be beneficial by preventing loss of infusate into the cyst cavity. 20 Here, we present a case of a diffuse intrinsic pontine glioma (DIPG) with an intratumoral cyst and discuss the resulting effects on drug distribution achieved using CED.
Case Report

Clinical History
This 7-year-old girl initially presented with intermittent morning headaches and gait instability. The patient was referred by her pediatrician to a neurologist, who noted a right cranial nerve VI palsy and right hemiparesis, as well as horizontal nystagmus. The patient underwent MRI of the brain, which demonstrated an infiltrative expansile mass centered in the pons, consistent with DIPG. She was started on a regimen of dexamethasone and treated with conventional radiation therapy (59.4 Gy).
A 1-month posttreatment MRI study demonstrated reduction in tumor volume as well as a peripherally enhancing cystic area in the left pons. A follow-up MRI study obtained weeks later demonstrated an increase in the size of the cystic lesion, for which a drainage procedure was performed with simultaneous stereotactic tumor biopsy. Histological analysis was consistent with DIPG, and immunostaining was suggestive of the presence of H3K27M mutation.
Sequential MRI studies demonstrated asymptomatic recurrence of the cyst. After informed consent, the patient was enrolled into the Phase 1 study, "Convection-Enhanced Delivery of 124I-8H9 for Patients with Non-Progressive Diffuse Pontine Gliomas Previously Treated with External Beam Radiation Therapy" (clinical trial registration no. NCT01502917, clinicaltrials.gov). She underwent infusion of 4000 mCi of 124 I-8H9 at a maximal rate of 5 μl/min without any adverse events 27 days after the cyst drainage procedure. Given her stable disease status, the patient qualified for and underwent a second treatment with the same infusion parameters 2 months later.
Operation
The surgical planning procedure for the infusion catheter (Brainlab Flexible Catheter) was performed using iPlan Flow (Brainlab), FDA-approved software specifically designed to support the planning of intracranial drug delivery. MRI-guided stereotactic placement of the catheter was performed after induction of general anesthesia and using the ClearPoint system (MRI Interventions, Inc.), an MRI-compatible skull-mounted guidance device, which has previously been described in detail. 15 The insertion was performed in the BrainSuite (Brainlab), an intraoperative imaging suite that includes a 1.5-T Siemens scanner (Siemens AG). The catheter has a stylet that is removed following placement, allowing distal flexibility. Once the catheter is in place, a bone anchor is used to secure the catheter, and the guidance device can be removed. The infusion of 124 I-8H9 with co-infusion of Gd-DTPA (0.5 mol/L Magnevist [Bayer Schering Pharma], diluted in saline to a concentration of 5 mmol/L), was administered via CED outside the MR environment in a monitored setting at a maximal rate of 5 μl/min. The patient experienced no acute toxicity or neurological complications.
Imaging Analysis
To assess agent distribution, MRI (high-resolution T1-weighted imaging with and without intravenous contrast, T2-weighted imaging, diffusion tensor imaging, and FLAIR imaging, slices ≤ 3 mm) was performed as soon as possible after completion of infusion (< 2 hours). For analysis of the Gd-DTPA infusion, the postinfusion MR images were imported into the iPlan Flow planning software and merged with the pre-and intraoperative images using the automatic imaging fusion functionality of the software.
T2-weighted, T1-weighted, and FLAIR images were the basis to identify the volume of the cystic component and the target region in iPlan Flow (Fig. 1) . The actual infusate distribution was analyzed on the high-resolution T1-weighted MR and FLAIR images. The volume of distribution was segmented by applying a custom-made semiautomatic segmentation algorithm involving background subtraction and normalization.
Analysis of the MR images obtained in this patient reveals convective distribution in a radial arrangement around the catheter tip and with an ellipsoid configuration that is consistent with the longitudinal fiber tracts through the brainstem (Fig. 2) . Importantly, no surrogate tracer was detected within the intratumoral cyst (Fig. 3) .
10
Discussion
In the pediatric population, brainstem tumors account for 10%-20% of all CNS cancers. These tumors are further subdivided into low-grade focal brainstem gliomas and DIPGs. 8 DIPGs, which account for 80% of all brainstem tumors, typically arise in 7-to 9-yearold children, with no preference regarding sex. These tumors typically present as a progressive accumulation of symptoms characteristic of cerebellar dysfunction and cranial nerve palsies (most frequently cranial nerves VI and VII), such as ataxia, facial weakness, diplopia, and hearing loss. 3, 6, 11, 21, 22 A diagnosis of DIPG is traditionally made based on clinical presentation and MRI findings. Palliative radiation therapy is currently the standard of care. Because of its diffuse infiltrative nature and eloquent location, a DIPG is not amenable to resection. Clinical trials of various chemotherapeutic agents with and without radiation have failed to show a benefit. The mean overall survival of patients with DIPG is estimated at 9-14 months after diagnosis, and even the most aggressive radiotherapy regimen can prolong this time only by 3-6 months.
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The relative impermeability of the BBB to systemically administered chemotherapeutic agents presents a challenge in the treatment of CNS malignancies. Strategies to overcome this hurdle and deliver local therapy, such as BBB disruption with mannitol or focused ultrasound, have shown some promise. 4, 21 Preliminary studies have suggested that CED is a safe and effective method of overcoming the BBB and achieving high local concentrations of the drug. CED uses positive pressure to overcome the limitations of diffusion and simulate bulk molecular flow, which can be monitored in real time with a co-infusion of imaging tracers. 2, 5, 7, 9, 12, 13 Limitations of CED include factors such as a balance of infusion rate that reaches a reasonable area of distribution but does not lead to edema or neurological injury, as well as the complexity associated with precise placement of the catheter in a deep eloquent location. 12, 18 Multiple studies have examined the effects of pial and ependymal surfaces on drug distribution using CED. Using injections of both high-molecular-weight (HMW) and low-molecular-weight compounds into the brains of nonhuman primates, Jagannathan et al. demonstrated leakage into the subarachnoid space through pial and ependymal surfaces regardless of particle size. 10 However, Sampson et al. found that pial surfaces can prevent HMW compounds from entering the subarachnoid space, provided that the pial surface is not punctured during catheter placement. 18 The effect of drug "leaking" into the CSF presents a limitation for this method of drug delivery that should be considered as a factor in treating tumors located close to this boundary. In the case presented, the shortest distance from the catheter tip to the cavity wall was more than 10 mm, which is similar to the previously reported recommended minimum distance from fluid-filled structures for CED. 14, 17 Based on such studies, it has been postulated that cystic lesions within the target region might behave similarly to the subarachnoid space and serve as a low-pressure conduit into which infusate might preferentially pool, creating a barrier in volume and concentration of drug that can be delivered. In the case presented, we observed convective distribution around the catheter tip over a clinically relevant volume of the brainstem. However, despite prevailing theory, there was no evidence of infusate leakage into the tumor cyst.
It is well known that the coadministration of tracers to estimate drug distribution is a useful strategy but has its own limitations. For example, Gd-DTPA is a smaller molecule than the therapeutic infusate in this case ( 124 I-8H9), a radiolabeled antibody, and therefore may overestimate drug distribution. Our group and others are currently studying alternative strategies to overcome this limitation and achieve more accurate monitoring of infusate distribution at the target.
Our experience in this case suggests that cystic lesions may not adversely affect CED drug distribution and therefore can be treated successfully with this strategy. More thorough investigation is needed to precisely define circumstances in which cystic lesions do not impact drug delivery and distribution and may allow for definition of minimum distance guidelines for CED targeting in relation to cystic structures. The intracystic pressures may differ from those pressures in the subarachnoid space or ventricular compartments.
1 Further evaluation of drug distribution in a larger series will help better define these phenomena.
One limitation of this case report is that the nature of the cyst and its permeability could be patient-specific, and this outcome would not be widely generalizable to this population. However, further investigation in a larger series with additional preclinical experimental evaluations of drug distribution is needed to validate the hypotheses generated by this case report. This knowledge may aid in identifying patients who are candidates for CED as well as specific anatomical anomalies that may hinder successful treatment.
